Amgen price hikes to offset Aranesp payment drop

A new Medicare payment scheme for dialysis will likely result in a revenue drop for Amgen from its kidney disease treatment Aranesp. To compensate, the drugmaker has raised prices on several drugs.

Aranesp itself gets a 4.4 percent boost, reports Bloomberg. Prices on chemo-effect treatments Neulasta and Neupogen jump 2.9 percent.

Medicare cost controls have yielded a new payment scheme for dialysis treatment. In addition, Amgen suffered a 15 percent drop in sales of Aranesp in 2009, according to the report.

- here's the story

Suggested Articles

Cadila Healthcare is looking for outside manufacturing partners to add 70 million doses of its experimental COVID-19 vaccine to its arsenal.

The COVID-19 pandemic has disrupted another biopharma company's plan to launch a new medicine.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.